JMT106 Injection in the Treatment of Advanced Solid Tumors

This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors

Trial Details

NCT ID
NCT07275073
Phase
PHASE1
Sponsor
Shanghai JMT-Bio Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • JMT106 Injection
Locations (sample)
  • Zhejiang, China|25.3238,105.583

Key Eligibility Criteria

  • Age ≥18 years.
  • Histologically or cytologically confirmed advanced solid tumor.
  • Failure of at least one line of standard therapy, or no standard treatment available, or intolerant to standard treatment at the current stage.
  • At least one measurable lesion according to RECIST 1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →